Villefranche Sur Saone Cedex

• Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage: a randomised, doub … Pending
  2024-515663-59-00 5 intracerebral haemorrhage
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Pending
  2025-520565-51-00 5 small cell lung cancer
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting
  2025-521775-31-00 5 2025-11-12 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting
  2023-506235-15-00 5 2024-11-07 Limited-Stage Small-Cell Lung Cancer (LS SCLC)
• Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting
  2023-503523-25-00 4 2024-02-29 Non-small cell lung cancer
• A Study to evaluate the long-term safety and tolerability of tozorakimab in patients with chronic obstructive pulmonary disease (COPD) and a … Recruiting
  2025-523690-41-00 5 2026-05-04 Chronic Obstructive Pulmonary Disease (COPD)
• PIPELINE-RSV-France Recruiting
  2025-521755-23-00 5 2026-04-28 Respiratory syncytial virus infection
• A Study of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis Recruiting
  2024-519820-26-00 4 2026-01-22 Hallucinations and Delusions Associated with Alzheimer’s Disease Psych
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting
  2025-520747-32-00 5 2025-10-29 Mild to moderate Alzheimer’s Disease
• OPEN-LABEL PHASE II EFFICACY STUDY OF REPOTRECTINIB IN FRAIL (PS ≥2) AND /OR ELDERLYPATIENTS WITH ROS1-REARRANGED ADVANCED NSCLC Recruiting
  2023-509073-23-00 4 2024-10-01 Stage III/IV non-small-cell lung cancer (NSCLC) harboring an ROS1 gene
• FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and … Recruiting
  2023-506590-35-00 4 2024-06-13 Large-Cell NeuroEndocrine Carcinoma of the lung
• A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting
  2023-503376-24-00 5 2024-03-20 Metastatic non-small cell lung cancer (NSCLC)
• Short Treatment With Omalizumab for Severe Asthma (SHORTEN) Recruiting
  2024-513427-17-00 6 2021-05-20 Well controlled severe allergic asthma
• BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part … Ended recruitment
  2024-515740-23-00 5 2025-03-25 Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
• Durvalumab (immunotherapy) maintenance after thoracic chemoradiotherapy (CRT) in frail small cell lung cancer patients whose disease is limi … Ended recruitment
  2024-512224-11-00 4 2023-03-24 Histologically confirmed frail Limited Disease Small Cell Lung Cancer
• Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended recruitment
  2023-509429-37-00 5 2022-10-03 Advanced or Metastatic Non-Small Cell Lung Cancer
• IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot … Ended recruitment
  2023-510387-13-00 4 2022-05-18 advanced ALK-positive non-small cell lung cancer
• Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer Ended recruitment
  2024-515944-22-00 4 2021-01-19 BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment
  2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
• Rituximab from the first episode of Minimal Change Nephrotic Syndrome for preventing relapse risk in adult patients Ended recruitment
  2024-516102-36-00 4 2020-07-29 Minimal Change Nephrotic Syndrom
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)

Showing 1–23 of 23 trials